Faculty introduction - Tatsuya Kawaguchi |

Tatsuya Kawaguchi

Department / Course

Faculty of Health Science Department of Medical Technology

Graduate School of Health Sciences Division of Health Sciences

Center for Career Education

Job Professor

Selected Publications
Books	Pathogenesis of cloncal dominance in PNH: Selection mechanism in PNH. Paroxysmal Nocturnal Hemoglobinuria. From Bench to Bedside(Eds. Kanakura Y et al.). 2017, Tokyo.,pp.215-228 (Co-authored) 2017
Papers	Persistence of Colistin Resistance and mcr-1.1-Positive E. coli in Poultry Despite Colistin Ban in Japan Antibiotics 14 (4),pp.360 (Co-authored) 2025/04/01
Papers	JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN) Int J Hematol 121 (1),pp.5-38 (Co-authored) 2025/01
Papers	Antibiotic spectrum coverage scoring as a potential metric for evaluating the antimicrobial stewardship team activity: a single-center study Infect Control Hosp Epidemiol 45 (11),pp.1-9 (Co-authored) 2024/10
Papers	A micro-disc-based multiplex method for monitoring emerging SARS-CoV-2 variants using the molecular diagnostic tool Intelli-OVI Commun Med (Lond) 4 (1),pp.161 (Co-authored) 2024/08
Papers	Antibody responses to multiple doses of the mRNA-1273 COVID-19 vaccine (Moderna) in staff of a health science university in Japan Journal of Kumamoto Health Science University,pp.13-24 (Co-authored) 2024/03
Papers	A longitudinal analysis of paroxysmal nocturnal haemoglobinuria- type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan. Br J Haematol 203 (3),pp.468-476 (Co-authored) 2023/11
Papers	Management and risk factors for pleural effusion in Japanese patients with chronic myeloid leukemia treated with first-line dasatinib in real-world clinical practice. Intern Med 62 (22),pp.3299-3303 (Co-authored) 2023/11
Papers	Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol 118 (4),pp.419-431 (Co-authored) 2023/10
Papers	Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects. Int J Hematol 118 (2),pp.210-220 (Co-authored) 2023/08
Papers	Helicobacter kumamotonensis sp. nov., isolated from human clinical specimens. Int J Syst Evol Microbiol 73 (3) (Co-authored) 2023/05
Papers	Artificial cerebrospinal fluid restores aspirin-inhibited physiological hemostasis through recovery of platelet aggregation function. Acta Neurochir (Wien) 165 (5),pp.1269-1276 (Co-authored) 2023/03
Papers	Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML. Cancer Sci 114 (3),pp.995-1006 (Co-authored) 2023/03
Papers	Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Ann Med 54 (1),pp.1244-1254 (Co-authored) 2022/12
Papers	A SARS-CoV-2 Delta variant containing mutation in the probe binding regions used for RT-qPCR test in Japan exhibited atypical PCR amplification and might induce false negative result. J Infect Chemother 28 (5),pp.669-677 (Co-authored) 2022/05
Papers	Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. Int J Hematol 115 (4),pp.470-480 (Co-authored) 2022/04
Papers	The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure. Ann Hematol 100 (8),pp.1975-1982 (Co-authored) 2021/08
Papers	Impact of health policy on structural requisites for antimicrobial stewardship: A nationwide survey conducted in Japanese hospitals after enforcing the revised reimbursement system for antimicrobial stewardship programs. J Infect Chemother 27 (1),pp.1-6 (Co-authored) 2021/01
Papers	The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med 9 (23),pp.8931-8939 (Co-authored) 2020/12
Papers	Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). 112 (3),pp.268-291 (Co-authored) 2020/09
Papers	Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. Int J Hematol doi: 10.1007/s12185-022-03287-y (Co-authored) 2020
Papers	Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt). Int J Hematol 110 (6),pp.675-682 (Co-authored) 2019/12
Papers	Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis. 43 (6),pp.2836-2843 (Co-authored) 2019/12
Papers	Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis. Hematol Oncol 37 (3),pp.323-325 (Co-authored) 2019/08
Papers	Target investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol 109 (4),pp.426-439 (Co-authored) 2019/04
Papers	The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy. J Infect Chemother 25 (2),pp.83-88 (Co-authored) 2019/02
Papers	Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. Ann Hematol 97 (12),pp.2289-2297 (Co-authored) 2018/11
Papers	Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol 97 (11),pp.2081-2088 (Co-authored) 2018/11
Papers	Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis. Med Oncol 35 (11),pp.142 (Co-authored) 2018/09
Papers	Management of paroxysmal nocturnal hemoglobinuria: an update. (Review) Rinsho Ketsueki 59 (6),pp.703-710 (Sole-authored) 2018/07
Papers	Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial). Int J Hematol 107 (5),pp.535-540 (Co-authored) 2018/05
Papers	Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol 35 (7),pp.99 (Co-authored) 2018/05
Papers	Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma 59 (5),pp.1105-1112 (Co-authored) 2018/05
Papers	Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol 107 (6),pp.656-665 (Co-authored) 2018/02
Papers	Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol 35 (3),pp.38 (Co-authored) 2018/02
Papers	Isolated pancreatic myeloid sarcoma associated with t(8;21)/RUNX1-RUNX1T1 rearrangement. Intern Med 57 (4),pp.563-568 (Co-authored) 2018/02
Papers	Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group. Leukemia Research 54,pp.55-58 (Co-authored) 2017/01